CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Extracorporeal left hemicolectomy anastomosisWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1245 Intracorporeal left hemicolectomy anastomosis Wiki 1.00
drug888 Experimental drug Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D003110 Colonic Neoplasms NIH 0.71

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0003003 Colon cancer HPO 0.71

There is one clinical trial.

Clinical Trials


1 RESECTION AND INTRACORPOREAL ANASTOMOSIS IN LAPAROSCOPIC LEFT COLECTOMY AS AN ADAPTATION TO THE PANDEMIC CAUSED BY SARS-CoV-2 (COVID19). A COMPARATIVE COHORT STUDY

OBJECTIVE: The aim of the study is to demonstrate that the intracorporeal resection and anastomosis in left-sided colon cancer, sigma and upper rectum, is not inferior to extracoprporeal resection and anastomosis, in terms of anastomotic leakage. BACKGROUND: Due to the recent events of a pandemic respiratory disease secondary to infection by SARS-CoV-2 virus or coronavirus 19 (COVID19), surgeons have been forced to adapt our surgical procedures in order to minimize exposure to the virus as much as possible. Based on the recommendations in case of surgery in patients with highly contagious viral diseases, the latest studies suggest minimally invasive accesses to minimize the risk of contagion. One of the proposed measures is the performance of intracorporeal anastomoses. Therefore, given the extensive experience of our center in minimally invasive surgery and studies on the validation of intracorporeal anastomosis techniques in both laparoscopic surgery of the right colon and rectum (TaTME), and the study of advantages that they can provide to the patient, our intention is to apply it to surgery on the left colon, sigma and upper rectum. Our hypothesis is that exteriorization of the colon through an accessory incision increases the risk of tension at the mesocolon level, thus increasing the risk of vascular deficit at the level of the staple area and it may increase the rate of anastomotic leakage. In this sense, studies that validate a standard technique of intracorporeal anastomosis in left colon surgery and that demonstrate its benefit with respect to extracorporeal anastomosis are lacking. We intend to describe a new intracorporeal anastomosis technique (ICA) that is feasible and safe for the patient and that can be applied universally. Once the ICA technique is established, it will allow us to determine its non-inferiority compared to the standard technique performed up to now with extracorporeal anastomosis. METHODS: All consecutive patients with left-sided, sigma and upper rectum adenocarcinoma will be included into a prospective cohort and treated by laparoscopy with totally intracorporeal resection and anastomosis. They will be compared with a retrospective cohort of consecutive patients of identical characteristics treated by laparoscopy with extracorporeal resection and anastomosis, in the immediate chronological period.

NCT04456933 Colon Cancer Procedure: Extracorporeal left hemicolectomy anastomosis Procedure: Intracorporeal left hemicolectomy anastomosis
MeSH:Colonic Neoplasms
HPO:Colon cancer Neoplasm of the colon

Primary Outcomes

Description: Percentage of anastomic leak (defined in accordance with Peel et al.).

Measure: Percentage of anastomotic leak (AL)

Time: 30 days

Secondary Outcomes

Description: Dindo-Clavien Classification

Measure: Rate of global morbidity

Time: 30 days

Description: SSI in accordance with the Center for Disease Control (CDC) National

Measure: Rate of Surgical site infection

Time: 30 days

Description: Percentage of re-interventions due to surgical complications

Measure: Rate of Re-interventions

Time: 30 days


Related HPO nodes (Using clinical trials)